Abstract
Prostaglandin signaling controls a wide range of biological processes from blood pressure homeostasis to inflammation and resolution thereof to the perception of pain to cell survival. Disruption of normal prostanoid signaling is implicated in numerous disease states. Prostaglandin signaling is facilitated by G-protein-coupled, prostanoid-specific receptors and the array of associated G-proteins. This review focuses on the expression, characterization, regulation, and mechanism of action of prostanoid receptors with particular emphasis on human isoforms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abramovitz M, Adam M, Boie Y, Carrière M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, Metters KM (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483:285–293. https://doi.org/10.1016/S1388-1981(99)00164-X
Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R (1994) Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269:2632–2636
Adam M, Boie Y, Rushmore TH, Müller G, Bastien L, McKee KT, Metters KM, Abramovitz M (1994) Cloning and expression of three isoforms of the human EP3 prostanoid receptor. FEBS Lett 338:170–174. https://doi.org/10.1016/0014-5793(94)80358-7
Af Forselles KJ, Root J, Clarke T, Davey D, Aughton K, Dack K, Pullen N (2011) In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist. Br J Pharmacol 164:1847–1856. https://doi.org/10.1111/j.1476-5381.2011.01495.x
Anderson LE, Schultz MK, Wiltbank MC (1999) Prostaglandin moieties that determine receptor binding specificity in the bovine corpus luteum. J. Reprod. Fertil. 116:133–141. https://doi.org/10.1530/jrf.0.1160133
Angulo J, Cuevas P, La Fuente JM, Pomerol JM, Ruiz-Castañé E, Puigvert A, Gabancho S, Fernández A, Ney P, Sáenz De Tejada I (2002) Regulation of human penile smooth muscle tone by prostanoid receptors. Br J Pharmacol 136:23–30. https://doi.org/10.1038/sj.bjp.0704675
Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N, Yeh L-SL (2017) UniProt: the universal protein knowledgebase. Nucleic Acids Res. 45:D158–D169. https://doi.org/10.1093/nar/gkh131
Arimura A, Yasui K, Kishino J, Asanuma F, Hasegawa H, Kakudo S, Ohtani M, Arita H (2001) Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J Pharmacol Exp Ther 298:411–419
Armstrong RA, Humphrey PP, Lumley P (1993) Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets. Br J Pharmacol 110:539–547. https://doi.org/10.1111/j.1476-5381.1993.tb13844.x
Arner M, Högestätt ED, Uski TK (1991) Characterization of contraction-mediating prostanoid receptors in human hand veins: effects of the thromboxane receptor antagonists BM13,505 and AH23848. Acta Physiol Scand 141:79–86. https://doi.org/10.1111/j.1748-1716.1991.tb09047.x
Baxter GS, Clayton JK, Coleman RA, Marshall K, Sangha R, Senior J (1995) Characterization of the prostanoid receptors mediating constriction and relaxation of human isolated uterine artery. Br J Pharmacol 116:1692–1696. https://doi.org/10.1111/j.1476-5381.1995.tb16393.x
Becker KP, Garnovskaya M, Gettys T, Halushka PV (1999) Coupling of thromboxane A2 receptor isoforms to Galpha13: effects on ligand binding and signalling. Biochim Biophys Acta 1450:288–296. https://doi.org/10.1016/S0167-4889(99)00068-3
Bilson HA, Mitchell DL, Ashby B (2004) Human prostaglandin EP3 receptor isoforms show different agonist-induced internalization patterns. FEBS Lett 572:271–275. https://doi.org/10.1016/j.febslet.2004.06.089
Binda C, Génier S, Cartier A, Larrivée JF, Stankova J, Young JC, Parent JL (2004) A G protein-coupled receptor and the intracellular synthase of its agonist functionally cooperate. J Cell Biol 204:377–393. https://doi.org/10.1083/jcb.201304015
Binda C, Parent JL (2015) Characterization of the interaction between the prostaglandin D2 DP1 receptor and the intracellular L-prostaglandin D synthase. Methods Mol Biol 1234:53–67. https://doi.org/10.1007/978-1-4939-1755-6_6
Blom N, Gammeltoft S, Brunak S (1999) Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 294:1351–1362. https://doi.org/10.1006/jmbi.1999.3310
Blom N, Sicheritz-Pontén T, Gupta R, Gammeltoft S, Brunak S (2004) Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4:1633–1649. https://doi.org/10.1002/pmic.200300771
Böer U, Neuschäfer-Rube F, Möller U, Püschel GP (2000) Requirement of N-glycosylation of the prostaglandin E2 receptor EP3beta for correct sorting to the plasma membrane but not for correct folding. Biochem J 350:839–847. https://doi.org/10.1042/bj3500839
Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M (1995) Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 270:18910–18916. https://doi.org/10.1074/jbc.270.32.18910
Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41:661–690. https://doi.org/10.1146/annurev.pharmtox.41.1.661
Capra V, Busnelli M, Perenna A, Ambrosio M, Accomazzo MR, Galés C, Chini B, Rovati GE (2013) Full and partial agonists of thromboxane prostanoid receptor unveil fine tuning of receptor superactive conformation and G protein activation. PLoS One 8:e60475. https://doi.org/10.1371/journal.pone.0060475
Chakraborty R, Pydi SP, Gleim S, Bhullar RP, Hwa J, Dakshinamurti S, Chelikani P (2013) New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-G protein coupling. Mol Cell Biol 33:184–193. https://doi.org/10.1128/MCB.00725-12
Chang SW, Reddy V, Pereira T, Dean BJ, Xia YQ, Seto C, Franklin RB, Karanam BV (2007) The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica 37:514–533. https://doi.org/10.1080/00498250601175565
Chun KS, Lao HC, Trempus CS, Okada M, Langenbach R (2009) The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. Carcinogenesis 30:1620–1627. https://doi.org/10.1093/carcin/bgp168
Crider JY, Griffin BW, Sharif NA (2000) Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization. Prostaglandins Leukot. Essent. Fatty Acids 62:21–26. https://doi.org/10.1054/plef.1999.0120
Crider JY, Xu SX, Sharif NA (2001) Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets. Prostaglandins Leukot Essent Fatty Acids 65:253–258. https://doi.org/10.1054/plef.2001.0322
Cserzo M, Eisenhaber F, Eisenhaber B, Simon I (2002) On filtering false positive transmembrane protein predictions. Protein Eng 15:745–752. https://doi.org/10.1093/protein/15.9.745
Desai S, April H, Nwaneshiudu C, Ashby B (2000) Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. Mol Pharmacol 58:1279–1286. https://doi.org/10.1124/mol.58.6.1279
Dey I, Lejeune M, Chadee K (2006) Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol 149:611–623. https://doi.org/10.1038/sj.bjp.0706923
Donnellan PD, Kinsella BT (2009) Immature and mature species of the human Prostacyclin Receptor are ubiquitinated and targeted to the 26S proteasomal or lysosomal degradation pathways, respectively. J Mol Signal 4:7. https://doi.org/10.1186/1750-2187-4-7
Dorn GW 2nd (1989) Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets. J Clin Invest 84:1883–1891. https://doi.org/10.1172/JCI114375
Dorn GW 2nd (1991) Tissue- and species-specific differences in ligand binding to thromboxane A2 receptors. Am J Physiol 261:R145–R153. https://doi.org/10.1152/ajpregu.1991.261.1.R145
Eivers SB, Kinsella BT (2016) Regulated expression of the prostacyclin receptor (IP) gene by androgens within the vasculature: Combined role for androgens and serum cholesterol. Biochim Biophys Acta 1859:1333–1351. https://doi.org/10.1016/j.bbagrm.2016.06.011
Emery DL, Djokic TD, Graf PD, Nadel JA (1989) Prostaglandin D2 causes accumulation of eosinophils in the lumen of the dog trachea. J Appl Physiol 67:959–962. https://doi.org/10.1152/jappl.1989.67.3.959
Feng JF, Rhee SG, Im MJ (1996) Evidence that phospholipase delta1 is the effector in the Gh (transglutaminase II)-mediated signaling. J Bio Chem. 271:16451–16454. https://doi.org/10.1074/jbc.271.28.16451
Ferguson SS (2007) Phosphorylation-independent attenuation of GPCR signaling. Trends Pharmacol Sci 28:73–179. https://doi.org/10.1016/j.tips.2007.02.008
Fitscha P, Tiso B, Krais T, Sinzinger H (1987) Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD)B. In: Samuelsson, R. Paloetti, P.W. Ramwell (eds). Adv Prostaglandin Thromboxane Leukot Res, Raven Press, New York 17A:450–454
Fujino H, Regan JW (2006) EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol Pharmacol 69:5–10. https://doi.org/10.1124/mol.105.017749
Fujino H, West KA, Regan JW (2002) Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem 277:2614–2619. https://doi.org/10.1074/jbc.M109440200
Fujino H, Xu W, Regan JW (2003) Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 278:12151–12156. https://doi.org/10.1074/jbc.M212665200
Gallant MA, Slipetz D, Hamelin E, Rochdi MD, Talbot S, de Brum-Fernandes AJ, Parent JL (2007) Differential regulation of the signaling and trafficking of the two prostaglandin D2 receptors, prostanoid DP receptor and CRTH2. Eur J Pharmacol 557:115–123. https://doi.org/10.1016/j.ejphar.2006.11.058
Ganesh T (2014) Prostanoid receptor EP2 as a therapeutic target. J Med Chem 57:4454–4465. https://doi.org/10.1021/jm401431x
George RJ, Sturmoski MA, Anant S, Houchen CW (2007) EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 83:112–120. https://doi.org/10.1016/j.prostaglandins.2006.10.005
Gervais FG, Morello JP, Beaulieu C, Sawyer N, Denis D, Greig G, Malebranche AD, O'Neill GP (2005) Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol 67:1834–1839. https://doi.org/10.1124/mol.104.009068
Giguère V, Gallant MA, de Brum-Fernandes AJ, Parent JL (2004) Role of extracellular cysteine residues in dimerization/oligomerization of the human prostacyclin receptor. Eur J Pharmacol 494:11–22. https://doi.org/10.1016/j.ejphar.2004.04.041
Giovanazzi S, Accomazzo MR, Letari O, Oliva D, Nicosia S (1997) Internalization and down-regulation of the prostacyclin receptor in human platelets. Biochem J 325:71–77. https://doi.org/10.1042/bj3250071
Gluais P, Lonchampt M, Morrow JD, Vanhoutte PM, Feletou M (2005) Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol 146:834–845. https://doi.org/10.1038/sj.bjp.0706390
Griffin BW, Magnino PE, Pang IH, Sharif NA (1998) Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J Pharmacol Exp Ther 286:411–418
Habib A, FitzGerald GA, Maclouf J (1999) Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 274:2645–2651. https://doi.org/10.1074/jbc.274.5.2645
Habib A, Vezza R, Créminon C, Maclouf J, FitzGerald GA (1997) Rapid, agonist-dependent phosphorylation in vivo of human thromboxane receptor isoforms. Minimal involvement of protein kinase C. J Biol Chem 272:7191–7200. https://doi.org/10.1074/jbc.272.11.7191
Hadházy P, Nagy L, Dömötör L, Magyar K (1986) Effects of indomethacin, prostaglandins E2 and I2 on the tone of human isolated femoral arteries. Eur J Clin Invest 16:248–251. https://doi.org/10.1111/j.1365-2362.1986.tb01337.x
Hanyaloglu AC, von Zastrow M (2008) Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmaco Toxicol. 48:537–568. https://doi.org/10.1146/annurev.pharmtox.48.113006.094830
Hata AN, Lybrand TP, Breyer RM (2005) Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. J Biol Chem 280:32442–32451. https://doi.org/10.1074/jbc.M502563200
Hata AN, Zent R, Breyer MD, Breyer RM (2003) Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther 306:463–470. https://doi.org/10.1124/jpet.103.050955
Hébert RL, Carmosino M, Saito O, Yang G, Jackson CA, Qi Z, Breyer RM, Natarajan C, Hata AN, Zhang Y, Guan Y, Breyer MD (2005) Characterization of a rabbit kidney prostaglandin F(2{alpha}) receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct. J Biol Chem 280:35028–35037. https://doi.org/10.1074/jbc.M505852200
Heemers HV, Verhoeven G, Swinnen JV (2006) Androgen activation of the sterol regulatory element-binding protein pathway: Current insights. Mol Endocrinol 20:2265–2277. https://doi.org/10.1210/me.2005-0479
Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M, Nagata K (2002) Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 168:981–985. https://doi.org/10.4049/jimmunol.168.3.981
Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193:255–261. https://doi.org/10.1084/jem.193.2.255
Hirai H, Abe H, Tanaka K, Takatsu K, Sugamura K, Nakamura M, Nagata K (2003) Gene structure and functional properties of mouse CRTH2, a prostaglandin D2 receptor. Biochem Biophys Res Commun 307:797–802. https://doi.org/10.1016/S0006-291X(03)01266-X
Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S (1994a) Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci U S A 91:11192–11196. https://doi.org/10.1073/pnas.91.23.11192
Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S (1994b) Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 94:1662–1667. https://doi.org/10.1172/JCI117510
Hirata T, Narumiya S (2011) Prostanoid receptors. Chem Rev 111:6209–6230. https://doi.org/10.1021/cr200010h
Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S (1996) Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 97:949–956. https://doi.org/10.1172/JCI118518
Honda A, Sugimoto Y, Namba T, Watabe A, Irie A, Negishi M, Narumiya S, Ichikawa A (1993) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J Biol Chem 268:7759–7762
Hsu SC, Chen LC, Kuo ML, Huang JL, Huang SK (2002) Novel SNPs in a candidate gene, CRTH2, for allergic diseases. Genes Immun 3:114–116. https://doi.org/10.1038/sj.gene.6363826
Ikegami R, Sugimoto Y, Segi E, Katsuyama M, Karahashi H, Amano F, Maruyama T, Yamane H, Tsuchiya S, Ichikawa A (2001) The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages. J Immunol 166:4689–4696. https://doi.org/10.4049/jimmunol.166.7.4689
Ito S, Okuda E, Sugama K, Negishi M, Hayaishi O (1990) Evaluation of ZK110841 and AH6809, an agonist and an antagonist of prostaglandin DP-receptors on human platelets, with a PGD2-responsive cell line from bovine embryonic trachea. Br J Pharmacol 99:13–14. https://doi.org/10.1111/j.1476-5381.1990.tb14645.x
Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW (2010) EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Mol Pharmacol 77:1025–1036. https://doi.org/10.1124/mol.110.063933
Jin J, Mao GF, Ashby B (1997) Constitutive activity of human prostaglandin E receptor EP3 isoforms. Br J Pharmacol 121:317–323. https://doi.org/10.1038/sj.bjp.0701121
Jones RL, Giembycz MA, Woodward DF (2009) Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J. Pharmacol 158:104–145. https://doi.org/10.1111/j.1476-5381.2009.00317.x
Kambe A, Iguchi G, Moon Y, Kamitani H, Watanabe T, Eling TE (2008) Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents. Biochim Biophys Acta 1783:1211–1219. https://doi.org/10.1016/j.bbamcr.2008.01.032
Kandola MK, Sykes L, Lee YS, Johnson MR, Hanyaloglu AC, Bennett PR (2014) EP2 receptor activates dual G protein signaling pathways that mediate contrasting proinflammatory and relaxatory responses in term pregnant human myometrium. Endocrinology 155:605–617. https://doi.org/10.1210/en.2013-1761
Kashmiry A, Tate R, Rotondo G, Davidson J, Rotondo D (2018) The prostaglandin EP4 receptor is a master regulator of the expression of PGE2 receptors following inflammatory activation in human monocytic cells. Biochim Biophys Acta Mol Cell Biol Lipids 1863:1297–1304. https://doi.org/10.1016/j.bbalip.2018.07.003
Kelley-Hickie LP, Kinsella BT (2004) EP1- and FP-mediated cross-desensitization of the alpha (alpha) and beta (beta) isoforms of the human thromboxane A2 receptor. Br J Pharmacol 142:203–221. https://doi.org/10.1038/sj.bjp.0705695
Kelley-Hickie LP, Kinsella BT (2006) Homologous desensitization of signalling by the beta (beta) isoform of the human thromboxane A2 receptor. Biochim Biophys Acta 1761:1114–1131. https://doi.org/10.1016/j.bbalip.2006.07.012
Kelley-Hickie LP, O'Keeffe MB, Reid HM, Kinsella BT (2007) Homologous desensitization of signalling by the alpha (alpha) isoform of the human thromboxane A2 receptor: a specific role for nitric oxide signalling. Biochim Biophys Acta 1773:970–989. https://doi.org/10.1016/j.bbamcr.2007.03.012
Kilfeather SA, Massarella A, Gorgolewska G, Ansell E, Turner P (1984) Beta-adrenoceptor and epoprostenol (prostacyclin) responsiveness of lymphocytes in migraine patients. Postgrad Med J 60:391–393. https://doi.org/10.1136/pgmj.60.704.391
Kinsella BT, O'Mahony DJ, FitzGerald GA (1994) Phosphorylation and regulated expression of the human thromboxane A2 receptor. J Biol Chem 269:29914–29919
Kinsella BT, O'Mahony DJ, Fitzgerald GA (1997) The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 281:957–964
Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122:217–224. https://doi.org/10.1038/sj.bjp.0701367
Kitanaka J, Hamano T, Gotoh M, Hashimoto H, Baba A (1994) Tunicamycin inhibits prostaglandin F2 alpha receptor-mediated phosphoinositide hydrolysis in cultured rat astrocytes. Neurochem Res 19:1545–1550
Kobzar G, Mardla V, Järving I, Samel N (2001) Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets. Cell Physiol Biochem 11:279–284. https://doi.org/10.1159/000047814
Konger RL, Scott GA, Landt Y, Ladenson JH, Pentland AP (2002) Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression. Am J Pathol 161:2065–2078. https://doi.org/10.1016/S0002-9440(10)64485-9
Kotani M, Tanaka I, Ogawa Y, Suganami T, Matsumoto T, Muro S, Yamamoto Y, Sugawara A, Yoshimasa Y, Sagawa N, Narumiya S, Nakao K (2000) Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus. J Clin Endocrinol Metab 85:4315–4322. https://doi.org/10.1210/jcem.85.11.6989
Kotani M, Tanaka I, Ogawa Y, Usui T, Mori K, Ichikawa A, Narumiya S, Yoshimi T, Nakao K (1995) Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol 48:869–879
Kotani M, Tanaka I, Ogawa Y, Usui T, Tamura N, Mori K, Narumiya S, Yoshimi T, Nakao K (1997) Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics 40:425–434. https://doi.org/10.1006/geno.1996.4585
Kozasa T, Gilman AG (1996) Protein kinase C phosphorylates G12 alpha and inhibits its interaction with G beta gamma. J Biol Chem 271:12562–12567. https://doi.org/10.1074/jbc.271.21.12562
Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, Bollag G, Sternweis PC (1998) p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 280:2109–2111. https://doi.org/10.1126/science.280.5372.2109
Kunapuli P, Lawson JA, Rokach J, FitzGerald GA (1997) Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor. Activation by the isoprostane, 12-iso-PGF2alpha. J Biol Chem 272:27147–27154. https://doi.org/10.1074/jbc.272.43.27147
Kunapuli P, Lawson JA, Rokach JA, Meinkoth JL, FitzGerald GA (1998) Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem 273:22442–22452. https://doi.org/10.1074/jbc.273.35.22442
Kunapuli SP, Fen Mao G, Bastepe M, Liu-Chen LY, Li S, Cheung PP, JK DR, Ashby B (1994) Cloning and expression of a prostaglandin E receptor EP3 subtype from human erythroleukaemia cells. Biochem J 298:263–267. https://doi.org/10.1042/bj2980263
Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Hoover J, Jang W, Katz K, Ovetsky M, Riley G, Sethi A, Tully R, Villamarin-Salomon R, Rubinstein W, Maglott DR (2016) ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44(D1):D862–D868. https://doi.org/10.1093/nar/gkv122
Larsen R, Hansen MB, Bindslev N (2005) Duodenal secretion in humans mediated by the EP4 receptor subtype. Acta Physiol Scand 185:133–140. https://doi.org/10.1111/j.1365-201X.2005.01471.x
Leduc M, Breton B, Galés C, Le Gouill C, Bouvier M, Chemtob S, Heveker H (2009) Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther 331:297–307. https://doi.org/10.1124/jpet.109.156398
Lee CM, Genetos DC, You Z, Yellowley CE (2007) Hypoxia regulates PGE(2) release and EP1 receptor expression in osteoblastic cells. J Cell Physiol 212:182–188. https://doi.org/10.1002/jcp.21017
Liang Y, Woodward DF, Guzman VM, Li C, Scott DF, Wang JW, Wheeler LA, Garst ME, Landsverk K, Sachs G, Krauss AH, Cornell C, Martos J, Pettit S, Fliri H (2008a) Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol 154:1079–1093. https://doi.org/10.1038/bjp.2008.142
Liang Z, Sooranna SR, Engineer N, Tattersall M, Khanjani S, Bennett PR, Myatt L, Johnson MR (2008b) Prostaglandin F2-alpha receptor regulation in human uterine myocytes. Mol Hum Reprod 14:215–223. https://doi.org/10.1093/molehr/gan008
Lim H, Dey SK (1997) Prostaglandin E2 receptor subtype EP2 gene expression in the mouse uterus coincides with differentiation of the luminal epithelium for implantation. Endocrinology 138:4599–4606. https://doi.org/10.1210/endo.138.11.5528
MacLean Scott E, Solomon LA, Davidson C, Storie J, Palikhe NS, Cameron L (2018) Activation of Th2 cells downregulates CRTh2 through an NFAT1 mediated mechanism. PLoS One 13:e0199156. https://doi.org/10.1371/journal.pone.0199156
Maher SA, Birrell MA, Adcock JJ, Wortley MA, Dubuis ED, Bonvini SJ, Grace MS, Belvisi MG (2015) Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events. Eur Respir J 45:1108–1118. https://doi.org/10.1183/09031936.00061614
Maiguel D, Faridi MH, Wei C, Kuwano Y, Balla KM, Hernandez D, Barth CJ, Lugo G, Donnelly M, Nayer A, Moita LF, Schürer S, Traver D, Ruiz P, Vazquez-Padron RI, Ley K, Reiser J, Gupta V (2011) Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal 4:ra57. https://doi.org/10.1126/scisignal.2001811
Manganello JM, Djellas Y, Borg C, Antonakis K (1999) G.C. Le Breton GC, Cyclic AMP-dependent phosphorylation of thromboxane A(2) receptor-associated Galpha(13). J Biol Chem 274:28003-28010. 0.1074/jbc.274.39.28003
Markovič T, Jakopin Ž, Dolenc MS, Mlinarič-Raščan I (2017) Structural features of subtype-selective EP receptor modulators. Drug Discov Today 22:57–71. https://doi.org/10.1016/j.drudis.2016.08.003
Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota F, Eisenhaber F (2007) Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol 3:e66. https://doi.org/10.1371/journal.pcbi.0030066
Mayeux PR, Morton HE, Gillard J, Lord A, Morinelli TA, Boehm A, Mais DE, Halushka PV (1988) The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets. Biochem Biophys Res Commun 157:733–739. https://doi.org/10.1016/S0006-291X(88)80311-5
McGraw DW, Mihlbachler KA, Schwarb MR, Rahman FF, Small KM, Almoosa KF, Liggett SB (2006) Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 116:1400–1409. https://doi.org/10.1172/JCI25840
McKenniff M, Rodger IW, Norman P, Gardiner PJ (1988) Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur J Pharmacol 153:149–159. https://doi.org/10.1016/0014-2999(88)90601-2
Meisdalen K, Dajani OF, Christoffersen T, Sandnes D (2007) Prostaglandins Enhance EGF-induced DNA synthesis in Hepatocytes by Stimulation of EP3 and FP Receptors. J Pharm Exp Ther 322:1044–1050. https://doi.org/10.1124/jpet.107.121277
Merz C, von Mässenhausen A, Queisser A, Vogel W, Andrén O, Kirfel J, Duensing S, Perner S, Nowak M (2016) IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2. Am J Pathol 186:974–984. https://doi.org/10.1016/j.ajpath.2015.12.009
Mesquita-Santos FP, Bakker-Abreu I, Luna-Gomes T, Bozza PT, Diaz BL, Bandeira-Melo C (2011) Co-operative signalling through DP(1) and DP(2) prostanoid receptors is required to enhance leukotriene C(4) synthesis induced by prostaglandin D(2) in eosinophils. Br J Pharmacol 162:1674–1685. https://doi.org/10.1111/j.1476-5381.2010.01086.x
Miggin SM, Kinsella BT (1998) Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1425:543–559. https://doi.org/10.1016/S0304-4165(98)00109-3
Miggin SM, Lawler OA, Kinsella BT (2002) Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur J Biochem 269:1714–1725. https://doi.org/10.1046/j.1432-1327.2002.02817.x
Miggin SM, Lawler OA, Kinsella BT (2003) Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem 278:6947–6958. https://doi.org/10.1074/jbc.M210637200
Miki I, Kishibayashi N, Nonaka H, Ohshima E, Takami H, Obase H, Ishii A (1992) Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol 59:357–364. https://doi.org/10.1254/jjp.59.357
Modesti PA, Colella A, Abbate R, Gensini G, Neri Serneri G (1989) Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol 169:85–93. https://doi.org/10.1016/0014-2999(89)90820-0
Monneret G, Gravel S, Diamond M, Rokach J (2001) Powell WS, Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98:1942–1948. https://doi.org/10.1182/blood.V98.6.1942
Morii H, Watanabe Y (1992) A possible role of carbohydrate moieties in prostaglandin D2 and prostaglandin E2 receptor proteins from the porcine temporal cortex. Arch Biochem Biophys 292:121–127. https://doi.org/10.1016/0003-9861(92)90059-6
Murray R, Shipp E, FitzGerald GA (1990) Prostaglandin endoperoxide/thromboxane A2 receptor desensitization. Cross-talk with adenylate cyclase in human platelets. J Biol Chem 265:21670–21675
Nagata K, Hirai H (2003) The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 69:169–177. https://doi.org/10.1016/S0952-3278(03)00078-4
Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, Yoshie O, Abe H, Tada K, Nakamura M, Sugamura K, Takano S (1999) Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 162:1278–1286
Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79:1193–1226. https://doi.org/10.1152/physrev.1999.79.4.1193
Nasrallah R, Hassouneh R, Zimpelmann J, Karam AJ, Thibodeau JF, Burger D, Burns KD, Kennedy CR, Hébert RL (2015) Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors. Lab Invest 95:1044–1055. https://doi.org/10.1038/labinvest.2015.79
Neuschäfer-Rube F, Engemaier E, Koch S, Böer U, Püschel GP (2003) Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J 371:443–449. https://doi.org/10.1042/bj20021429
Neuschäfer-Rube F, Hermosilla R, Rehwald M, Rönnstrand L, Schülein R, Wernstedt C, Püschel GP (2004) Identification of a Ser/Thr cluster in the C-terminal domain of the human prostaglandin receptor EP4 that is essential for agonist-induced beta-arrestin1 recruitment but differs from the apparent principal phosphorylation site. Biochem J 379:573–585. https://doi.org/10.1042/bj20031820
Nishigaki N, Negishi M, Honda A, Sugimoto Y, Namba T, Narumiya S, Ichikawa A (1995) Identification of prostaglandin E receptor 'EP2' cloned from mastocytoma cells EP4 subtype. FEBS Lett 364:339–341. https://doi.org/10.1016/0014-5793(95)00421-5
Nishigaki N, Negishi M, Ichikawa A (1996) Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol Pharmacol 50:1031–1037
Norel X, de Montpreville V, Brink C (2004) Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat 74:101–112. https://doi.org/10.1016/j.prostaglandins.2004.07.003
Offermanns S, Hu YH, Simon MI (1996) Galpha12 and galpha13 are phosphorylated during platelet activation. J Biol Chem 271:26044–26048. https://doi.org/10.1074/jbc.271.42.26044
Offermanns S, Laugwitz KL, Spicher K, Schultz G (1994) G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A 91:504–508. https://doi.org/10.1073/pnas.91.2.504
Ohmichi M, Koike K, Kimura A, Masuhara K, Ikegami H, Ikebuchi Y, Kanzaki T, Touhara K, Sakaue M, Kobayashi Y, Akabane M, Miyake A, Murata Y (1997) Role of mitogen-activated protein kinase pathway in prostaglandin F2alpha-induced rat puerperal uterine contraction. Endocrinology 138:3103–3111. https://doi.org/10.1210/endo.138.8.5305
O'Keeffe MB, Reid HM, Kinsella BT (2008) Agonist-dependent internalization and trafficking of the human prostacyclin receptor: a direct role for Rab5a GTPase. Biochim Biophys Acta 1783:1914–1928. https://doi.org/10.1016/j.bbamcr.2008.04.010
Okuda-Ashitaka E, Sakamoto K, Giles H, Ito S, Hayaishi O (1993) Cyclic-AMP-dependent Ca2+ influx elicited by prostaglandin D2 in freshly isolated nonchromaffin cells from bovine adrenal medulla. Biochim Biophys Acta 1176:148–154. https://doi.org/10.1016/0167-4889(93)90190-Z
Pándy-Szekeres G, Munk C, Tsonkov TM, Mordalski S, Harpsøe K, Hauser AS, Bojarski AJ, Gloriam DE (2018) GPCRdb in 2018: adding GPCR structure models and ligands. Nucleic Acids Res 46:D440–D446. https://doi.org/10.1093/nar/gkx1109
Parent JL, Labrecque P, Orsini MJ, Benovic JL (1999) Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem 274:8941–8948. https://doi.org/10.1074/jbc.274.13.8941
Peinhaupt M, Roula D, Theiler A, Sedej M, Schicho R, Marsche G, Sturm EM, Sabroe I, Rothenberg ME, Heinemann A (2018) DP1 receptor signaling prevents the onset of intrinsic apoptosis in eosinophils and functions as a transcriptional modulator. J Leukoc Biol 104:159–171. https://doi.org/10.1002/JLB.3MA1017-404R
Penn RB, Pascual RM, Kim YM, Mundell SJ, Krymskaya VP, Panettieri RA Jr, Benovic JL (2001) Arrestin specificity for G protein-coupled receptors in human airway smooth muscle. J Biol Chem 276:32648–32656. https://doi.org/10.1074/jbc.M104143200
Perchick GB, Jabbour HN (2003) Cyclooxygenase-2 overexpression inhibits cathepsin D-mediated cleavage of plasminogen to the potent antiangiogenic factor angiostatin. Endocrinology 144:5322–5328. https://doi.org/10.1210/en.2003-0986
Peri KG, Quiniou C, Hou X, Abran D, Varma DR, Lubell WD, Chemtob S (2002) THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol 26:389–397. https://doi.org/10.1053/sper.2002.37307
Pettipher R, Hansel TT, Armer R (2007) Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 6:313–325. https://doi.org/10.1038/nrd2266
Pierce KL, Fujino H, Srinivasan D, Regan JW (1999) Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J Biol Chem 274:35944–35949. https://doi.org/10.1074/jbc.274.50.35944
Pohl O, Chollet A, Kim SH, Riaposova L, Spézia F, Gervais F, Guillaume P, Lluel P, Méen M, Lemaux F, Terzidou V, Bennett PR, Gotteland JP (2018) OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor. J Pharmacol Exp Ther 366:349–364. https://doi.org/10.1124/jpet.118.247668
Rangachari PK, Betti PA, Prior ET, Roberts LJ 2nd (1995) Effects of a selective DP receptor agonist (BW 245C) and antagonist (BW A868C) on the canine colonic epithelium: an argument for a different DP receptor? J Pharmacol Exp Ther 275:611–617
Regan JW (2003) EP2 and EP4 prostanoid receptor signaling. Life Sci 74:143–153. https://doi.org/10.1016/j.lfs.2003.09.031
Regan JW, Bailey TJ, Donello JE, Pierce KL, Pepperl DJ, Zhang D, Kedzie KM, Fairbairn CE, Bogardus AM, Woodward DF, Gil DW (1994b) Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br J Pharmacol 112:377–385. https://doi.org/10.1111/j.1476-5381.1994.tb13082.x
Regan JW, Bailey TJ, Pepperl DJ, Pierce KL, Bogardus AM, Donello JE, Fairbairn CE, Kedzie KM, Woodward DF, Gil DW (1994a) Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 46:213–220
Ricciotti E, FitzGerald GA (2011) Prostaglandins and Inflammation. Arterioscler Thromb Vasc Biol 31:986–1000. https://doi.org/10.1161/ATVBAHA.110.207449
Sands WA, Palmer TM (2008) Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 20:460–466. https://doi.org/10.1016/j.cellsig.2007.10.005
Savage MA, Moummi C, Karabatsos PJ, Lanthorn TH (1993) SC-46275: a potent and highly selective agonist at the EP3 receptor. Prostaglandins Leukot Essent Fatty Acids 49:939–943. https://doi.org/10.1016/0952-3278(93)90179-Z
Sawyer N, Cauchon E, Chateauneuf A, Cruz RP, Nicholson DW, Metters KM, O'Neill GP, Gervais FG (2002) Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 137:1163–1172. https://doi.org/10.1038/sj.bjp.0704973
Schmid A, Thierauch KH, Schleuning WD, Dinter H (1995) Splice variants of the human EP3 receptor for prostaglandin E2. Eur J Biochem 228:23–30. https://doi.org/10.1111/j.1432-1033.1995.0023o.x
Schratl P, Royer JF, Kostenis E, Ulven T, Sturm EM, Waldhoer M, Hoefler G, Schuligoi R, Lippe IT, Peskar BA, Heinemann A (2007) The role of the prostaglandin D2 receptor, DP, in eosinophil trafficking. J Immunol 179:4792–4799. https://doi.org/10.4049/jimmunol.179.7.4792
Schröder R, Merten N, Mathiesen JM, Martini L, Kruljac-Letunic A, Krop F, Blaukat A, Fang Y, Tran E, Ulven T, Drewke C, Whistler J, Pardo L, Gomeza J, Kostenis E (2009) The C-terminal tail of CRTH2 is a key molecular determinant that constrains Gα and downstream signaling cascade activation. J Biol Chem 284(2):1324–1336. https://doi.org/10.1074/jbc.M806867200
Sekido N, Kida J, Mashimo H, Wakamatsu D, Okada H, Matsuya H (2016) Promising Effects of a Novel EP2 and EP3 Receptor Dual Agonist, ONO-8055, on Neurogenic Underactive Bladder in a Rat Lumbar Canal Stenosis Model. J Urol 196:609–616. https://doi.org/10.1016/j.juro.2016.02.064
Sharif NA, Crider JY, Xu SX, Williams GW (2000b) Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J Pharmacol Exp Ther 293:321–328
Sharif NA, Davis TL (2002) Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol 54:539–547. https://doi.org/10.1211/0022357021778655
Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX (2003) Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 19:501–515. https://doi.org/10.1089/108076803322660422
Sharif NA, Williams GW, Davis TL (2000a) Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand. Br J Pharmacol 131:1025–1038. https://doi.org/10.1038/sj.bjp.0703686
Shenker A, Goldsmith P, Unson CG, Spiegel AM (1991) The G protein coupled to the thromboxane A2 receptor in human platelets is a member of the novel Gq family. Trans Assoc Am Physicians 104:11–20
Siegl AM, Smith JB, Silver MJ, Nicolaou KC, Ahern D (1979) Selective binding site for [3H]prostacyclin on platelets. J Clin Invest 63:215–220. https://doi.org/10.1172/JCI109292
Smyth EM, Austin SC, Reilly MP, FitzGerald GA (2000) Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 275:32037–32045. https://doi.org/10.1074/jbc.M003873200
Smyth EM, Li WH, FitzGerald GA (1998) Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase C. J Biol Chem 273:23258–23266. https://doi.org/10.1074/jbc.273.36.23258
Smyth EM, Nestor PA, FitzGerald GA (1996) Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 271:33698–33704. https://doi.org/10.1074/jbc.271.52.33698
Sood R, Flint-Ashtamker G, Borenstein D, Barki-Harrington L (2014) Upregulation of prostaglandin receptor EP1 expression involves its association with cyclooxygenase-2. PLoS One 9:e91018. https://doi.org/10.1371/journal.pone.0091018
Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen MB, Schjoldager KT, Lavrsen K, Dabelsteen S, Pedersen NB, Marcos-Silva L, Gupta R, Bennett EP, Mandel U, Brunak S, Wandall HH, Levery SB (2013) Clausen H, Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J 32:1478–1488. https://doi.org/10.1038/emboj.2013.79
Stelzer G, Rosen R, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Iny Stein T, Nudel R, Lieder I, Mazor Y, Kaplan S, Dahary D, Warshawsky D, Guan-Golan Y, Kohn A, Rappaport N, Safran M, and Lancet D (2016) The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis. Current Protocols in Bioinformatics 54:1.30.1-1.30.33. https://doi.org/10.1002/cpbi.5
Stitham J, Arehart E, Elderon L, Gleim SR, Douville K, Kasza Z, Fetalvero K, MacKenzie T, Robb J, Martin KA, Hwa J (2011) Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction. J Biol Chem 286:7060–7069. https://doi.org/10.1074/jbc.M110.124933
Stitham J, Stojanovic A, Hwa J (2002) Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem 277:15439–15444. https://doi.org/10.1074/jbc.M201187200
Stürzebecher CS, Losert W (1987) Effects of Iloprost on Platelet Activation In Vitro. In: Gryglewski RJ, Stock G (eds) Prostacyclin and Its Stable Analogue Iloprost. Springer, Berlin, pp 39–45
Sugama K, Tanaka T, Yokohama H, Negishi M, Hayashi H, Ito S, Hayaishi O (1989) Stimulation of cAMP formation by prostaglandin D2 in primary cultures of bovine adrenal medullary cells: identification of the responsive population as fibroblasts. Biochim Biophys Acta 1011:75–80. https://doi.org/10.1016/0167-4889(89)90081-5
Suganami A, Fujino H, Okura I, Yanagisawa N, Sugiyama H, Regan JW, Tamura Y, Murayama T (2016) Human DP and EP2 prostanoid receptors take on distinct forms depending on the diverse binding of different ligands. FEBS 283:3853–4011. https://doi.org/10.1111/febs.13899
Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, Gantner F, Bacon KB (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 305:347–352. https://doi.org/10.1124/jpet.102.046748
Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem. 282:11613–11617. https://doi.org/10.1074/jbc.R600038200
Tachado SD, Zhang Y, Abdel-Latif AA (1993) Protein kinase C is involved in cyclic adenosine monophosphate formation due to PGF2 alpha desensitization in bovine iris sphincter. Invest Ophthalmol Vis Sci 34:2023–2032
Takayama K, García-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, Libby P (2002) Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277:44147–44154. https://doi.org/10.1074/jbc.M204810200
Tang CH, Yang RS, Fu WM (2005) Prostaglandin E2 stimulates fibronectin expression through EP1 receptor, phospholipase C, protein kinase Calpha, and c-Src pathway in primary cultured rat osteoblasts. J Biol Chem 280:22907–22916. https://doi.org/10.1074/jbc.M500130200
Tobin AB (2008) G-protein-coupled receptor phosphorylation: where, when and by whom. Br. J Pharmacol 153:S167–S176. https://doi.org/10.1038/sj.bjp.0707662
Tostes RC, Nigro D, Fortes ZB, Carvalho MH (2003) Effects of estrogen on the vascular system. Braz J Med Biol Res 36:1143–1158. https://doi.org/10.1590/S0100-879X2003000900002
Town MH, Casals-Stenzel J, Schillinger E (1983) Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. Prostaglandins 25:13–28. https://doi.org/10.1016/0090-6980(83)90131-4
Tsai AL, Hsu MJ, Vijjeswarapu H, Wu KK (1989) Solubilization of prostacyclin membrane receptors from human platelets. J Biol Chem 264:61–67
Tsuboi K, Sugimoto Y, Ichikawa A (2002) Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 68-69:535–556. https://doi.org/10.1016/S0090-6980(02)00054-0
Tunaru S, Chennupati R, Nüsing RM, Offermanns S (2016) Arachidonic Acid Metabolite 19(S)-HETE Induces Vasorelaxation and Platelet Inhibition by Activating Prostacyclin (IP) Receptor. PLoS One Sep 23;11(9):e0163633. https://doi.org/10.1371/journal.pone.0163633
Turner EC, Kinsella BT (2010) Estrogen increases expression of the human prostacyclin receptor within the vasculature through an ERalpha-dependent mechanism. J Mol Biol 396:473–486. https://doi.org/10.1016/j.jmb.2010.01.010
Tymkewycz PM, Jones RL, Wilson NH, Marr CG (1991) Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements. Br J Pharmacol 102:607–614. https://doi.org/10.1111/j.1476-5381.1991.tb12220.x
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist PH, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F (2015) Tissue-based map of the human proteome. Science 347:1260419. https://doi.org/10.1126/science.1260419
Ungrin MD, Carrière MC, Denis D, Lamontagne S, Sawyer N, Stocco R, Tremblay N, Metters KM, Abramovitz M (2001) Key structural features of prostaglandin E(2) and prostanoid analogs involved in binding and activation of the human EP(1) prostanoid receptor. Mol Pharmacol 59:1446–1456. https://doi.org/10.1124/mol.59.6.1446
Ushikubi F, Nakajima M, Hirata M, Okuma M, Fujiwara M, Narumiya S (1989a) Purification of the thromboxane A2/prostaglandin H2 receptor from human blood platelets. J Biol Chem 264:16496–16501
Ushikubi F, Nakajima M, Yamamoto M, Ohtsu K, Kimura Y, Okuma M, Uchino H, Fujiwara M, Narumiya S (1989b) [3H]S-145 and [125I]I-S-145-OH: new radioligands for platelet thromboxane A2 receptor with low nonspecific binding and high binding affinity for various receptor preparations. Eicosanoids 2:21–27
Ushikubi F, Nakamura K, Narumiya S (1994) Functional reconstitution of platelet thromboxane A2 receptors with Gq and Gi2 in phospholipid vesicles. Mol Pharmacol 46:808–816
Vassaux G, Gaillard D, Ailhaud G, Négrel R (1992) Prostacyclin is a specific effector of adipose cell differentiation. Its dual role as a cAMP- and Ca(2+)-elevating agent. J Biol Chem 267:11092–11097
Vezza R, Habib A, FitzGerald GA (1999) Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. J Biol Chem 274:12774–12779. https://doi.org/10.1074/jbc.274.18.12774
Vielhauer GA, Fujino H, Regan JW (2004) Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor. Arch Biochem Biophys 421:175–185. https://doi.org/10.1016/j.abb.2003.10.021
Walsh M, Foley JF, Kinsella BT (2000b) Investigation of the role of the carboxyl-terminal tails of the alpha and beta isoforms of the human thromboxane A(2) receptor (TP) in mediating receptor:effector coupling. Biochim Biophys Acta 1496:164–182. https://doi.org/10.1016/S0167-4889(00)00031-8
Walsh MT, Foley JF, Kinsella BT (1998) Characterization of the role of N-linked glycosylation on the cell signaling and expression of the human thromboxane A2 receptor alpha and beta isoforms. J Pharmacol Exp Ther 286:1026–1036
Walsh MT, Foley JF, Kinsella BT (2000a) The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization. J Bio Chem 275:20412–20423. https://doi.org/10.1074/jbc.M907881199
Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME (1998) Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A 95:4888–4893. https://doi.org/10.1073/pnas.95.9.4888
Wang L, Yao D, Deepak RNVK, Liu H, Xiao Q, Fan H, Gong W, Wei Z, Zhang C (2018) Structures of the Human PGD2 Receptor CRTH2 Reveal Novel Mechanisms for Ligand Recognition. Mol Cell 72:48–59. https://doi.org/10.1016/j.molcel.2018.08.009
Wang XL, Akhtar RA, Abdel-Latif AA (1995) Purification and properties of D-myo-inositol 1,4,5-trisphosphate 3-kinase from bovine iris sphincter smooth muscle: effects of protein phosphorylation in vitro and in intact muscle. Biochem J 308:1009–1016. https://doi.org/10.1042/bj3081009
Wheeldon A, Vardey CJ (1993) Characterization of the inhibitory prostanoid receptors on human neutrophils. Br J Pharmacol 108:1051–1054. https://doi.org/10.1111/j.1476-5381.1993.tb13504.x
Wikström K, Reid HM, Hill M, English KA, O'Keeffe MB, Kimbembe CC, Kinsella BT (2008) Recycling of the human prostacyclin receptor is regulated through a direct interaction with Rab11a GTPase. Cell Signal. 20:2332–2346. https://doi.org/10.1016/j.cellsig.2008.09.003
Wilson SJ, Roche AM, Kostetskaia E, Smyth EM (2004) Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem 279:53036–53047. https://doi.org/10.1074/jbc.M405002200
Woodward DF, Krauss AH, Chen J, Gil DW, Kedzie KM, Protzman CE, Shi L, Chen R, Krauss HA, Bogardus A, Dinh HT, Wheeler LA, Andrews SW, Burk RM, Gac T, Roof MB, Garst ME, Kaplan LJ, Sachs G, Pierce KL, Regan JW, Ross RA, Chan MF (2000) Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol 130:1933–1943. https://doi.org/10.1038/sj.bjp.0703462
Woodward DF, Krauss AH, Chen J, Liang Y, Li C, Protzman CE, Bogardus A, Chen R, Kedzie KM, Krauss HA, Gil DW, Kharlamb A, Wheeler LA, Babusis D, Welty D, Tang-Liu DD, Cherukury M, Andrews SW, Burk RM, Garst ME (2003) Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther 305:772–785. https://doi.org/10.1124/jpet.102.047837
Wright DH, Metters KM, Abramovitz M, Ford-Hutchinson AW (1998) Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol 123:1317–1324. https://doi.org/10.1038/sj.bjp.0701708
Xue I, Gyles SL, Barrow A, Pettipher R (2007) Inhibition of PI3K and calcineurin suppresses chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)-dependent responses of Th2 lymphocytes to prostaglandin D(2). Biochem Pharmacol 73:843–853. https://doi.org/10.1016/j.bcp.2006.11.021
Xue L, Barrow A, Pettipher R (2009) Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 182:7580–7586. https://doi.org/10.4049/jimmunol.0804090
Xue Y, Liu Z, Cao J, Ma Q, Gao X, Wang Q, Jin C, Zhou Y, Wen L, Ren J (2011) GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. Protein Eng Des Sel 24:255–260. https://doi.org/10.1093/protein/gzq094
Yu R, Xiao L, Zhao G, Christman JW, van Breemen RB (2011) Competitive enzymatic interactions determine the relative amounts of prostaglandins E2 and D2. J Pharmacol Exp Ther 339:716–725. https://doi.org/10.1124/jpet.111.185405
Zaccolo M (2009) cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol 158:50–60. https://doi.org/10.1111/j.1476-5381.2009.00185.x
Zeng L, An S, Goetzl EJ (1998) EP4/EP2 receptor-specific prostaglandin E2 regulation of interleukin-6 generation by human HSB.2 early T cells. J Pharmacol Exp Ther 286:1420–1426
Zhang Z, Austin SC, Smyth EM (2001) Glycosylation of the human prostacyclin receptor: role in ligand binding and signal transduction. Mol Pharmacol 60:480–487
Zhou F, Xue Y, Yao X, Xu Y (2006) CSS-Palm: palmitoylation site prediction with a clustering and scoring strategy (CSS). Bioinformatics 22:894–896. https://doi.org/10.1093/bioinformatics/btl013
Zhou H, Yan F, Tai HH (2001) Phosphorylation and desensitization of the human thromboxane receptor-alpha by G protein-coupled receptor kinases. J Pharmacol Exp Ther 298:1243–1251
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest/Competing interests
The author declares that he has no conflicts of interest or competing interests.
Ethics approval
Not applicable
Consent to participate
Not applicable
Consent for publication
Not applicable
Code availability
Not applicable
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Biringer, R.G. A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action. J. Cell Commun. Signal. 15, 155–184 (2021). https://doi.org/10.1007/s12079-020-00585-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-020-00585-0